Previous 10 |
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2020 Q4 earnings call. For further details see: Silence Therapeutics plc 2020 Q4 - Results - Earnings Call Presentation
Silence Therapeutics plc (SLN) Q4 2020 Results Earnings Conference Call March 30, 2021, 8:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Dr. Giles Campion - Head, R&D...
Silence Therapeutics (SLN): FY GAAP EPS of -39.80p.Revenue of £5.5M vs. £0.2M a year agoPress Release For further details see: Silence Therapeutics reports FY results
Silence Therapeutics (SLN) announced an oversubscribed private placement of 2.02M of ADSs; each representing three ordinary shares of 5 pence each in the capital at $22.50/ADS with new and existing institutional and accredited investors.Silence anticipates that the aggregate gross proceeds of...
Silence Therapeutics (SLN) has appointed Craig Tooman as CFO and member of the Executive Leadership Team, effective immediately. Most recently, Mr. Tooman was CFO and COO at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics. For further details see...
Silence Therapeutics (SLN) reports that the current CFO, Mr. Rob Quinn will leave the Company in January 2021 to take up a new position.The company has initiated a search for a Chief Financial Officer based in the United States. For further details see: Silence Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...